Mid-trial decisions to address unexpected issues—such as a product shortage—deserve to be made with all the facts. Often, those facts are hard to come by and require visibility to the entire supply chain. That was the case for one sponsor conducting a complex Phase III trial across a number of countries. Almac Clinical Technologies and Almac Clinical Services business units teamed up to provide a complete risk assessment and cost analysis of various solutions, making the most cost-effective choice obvious.